Moss Genomics Secures $250,000 Through Private Placement and Acquires 160 ETH

Moss Genomics Announces Private Placement Closing, 160 Ethereum Acquisition And Adds Hunter Jordan To Board Of Directors

- Advertisement -
  • Moss Genomics completes private placement raising $250,000 through issuance of 2.5 million shares at $0.10 each.
  • Company acquires 160 Ethereum cryptocurrency through issuance of 7.84 million common shares.
  • Hunter Jordan, a real estate investment executive with CPA background, joins the Board of Directors.
  • Company grants 200,000 stock options to directors, officers, and consultants at $0.20 exercise price.
  • Strategic move combines biotechnology with blockchain treasury management.

Moss Genomics Inc. (CSE: MOSS) (FSE: F73) has completed a dual-track expansion, securing traditional equity financing while simultaneously advancing into the cryptocurrency space through a significant Ethereum acquisition.

The biotechnology company’s private placement generated $250,000 through the issuance of 2.5 million common shares priced at $0.10 each. In a parallel move, Moss acquired 160 ETH by issuing 7.84 million common shares, marking a significant entry into cryptocurrency treasury management.

Hunter Jordan, newly appointed to the company’s Board of Directors, brings strategic oversight from his position as VP at a private real estate firm. His appointment strengthens Moss’s governance structure as it navigates the intersection of biotechnology and blockchain technology.

The company’s innovative approach combines Artificial Intelligence and genomic research with blockchain integration, representing a novel convergence in the life sciences sector. To incentivize leadership, Moss granted 200,000 stock options to key personnel, exercisable at $0.20 per share over five years.

These developments are subject to Canadian Securities Exchange final acceptance, with securities under a standard four-month-plus-one-day holding period. The company plans to utilize proceeds from both transactions for working capital purposes, advancing its unique position in the biotechnology-blockchain nexus.

For U.S. investors, these securities remain unregistered under the U.S. Securities Act, with trading restricted to non-U.S. persons unless qualifying for exemption status.

✅ Follow BITNEWSBOT on Telegram, Facebook, LinkedIn, X.com, and Google News for instant updates.

Previous Articles:

- Advertisement -
- Advertisement -
- Advertisement -

Latest

- Advertisement -

Must Read

Read Next
Recommended to you